Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D49KHP
|
|||
| Drug Name |
LNA043
|
|||
| Indication | Knee osteoarthritis [ICD-11: FA01; ICD-10: M15-M19, M47; ICD-9: 715] | Phase 2 | [1] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiopoietin-related protein 3 (ANGPTL3) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04864392) A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis. U.S.National Institutes of Health. | |||
| REF 2 | Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial. Nat Med. 2022 Dec;28(12):2633-2645. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.